Sun Pharma climbs about 2% as USFDA approves drug

NEW DELHI: Shares of pharma giant Sun Pharma jumped about 2 per cent in Tuesday's trade after the company received USFDA approval for selling Buprenorphine Hydrochloride in the United States market.

Reacting to the development, the stock rose 1.52 per cent to hit a high of Rs 883.45 on the BSE.

The company has also announced the sale of its CNS division received during the acquisition of Ranbaxy to Strides Arcolab in a filing to the BSE post market hours. The company had received approval from the Competition Commission of India on January 22 for the same.